



A LOCAL TREATMENT PROVEN TO REDUCE HEALING TIME¹



UrgoStart[®]
Foam Pad

An innovative non-adhesive, foam pad combining a polyurethane foam pad with a TLC-NOSF matrix.

A LOCAL TREATMENT PROVEN TO REDUCE HEALING TIME¹

The UrgoStart® treatment range of dressings is innovative technology combining Technology Lipido-Colloid (TLC) with Nano-Oligo Saccharide Factor (NOSF). Dressings in this range offer an optimum healing process.* The TLC-NOSF combination leads to the restoration of wound bed conditions that promote granulation of chronic wounds, in which a metabolic imbalance has led to a continuous degradation of the extra-cellular matrix, and possibly to delayed healing.

*The recommended treatment duration for UrgoStart® dressings 4-5 weeks or to healing.



UrgoStart® FOAM PAD



FEATURES

- Proven efficacy
- Incorporates NOSF technology
- Incorporates TLC technology
- Flexible & conformable
- Polyurethane Foam/
non-woven contact layer
- Seven day wear time
(dependent on level of exudate
and condition of wound)

BENEFITS

- Clinical Best Practice
- Inhibits proliferation of MMPs
- Promotes angiogenesis
- Creates a moist wound environment
- Non-adherent
- Atraumatic removal
- Assists in good fit on all wound shapes
- Suitable for deep and cavity wounds
- Provides protection to peri-wound area
- Offers high-level exudate management
- Can be cut
- Will not shed into the wound
- Reduces need for frequent dressing changes

INDICATIONS

- Low to moderately exuding (a secondary absorbent dressing can be used for heavily exuding wounds)
 - o Chronic wounds
 - o Diabetic foot ulcers
 - o Leg ulcers,
 - o Pressure injuries
- Long standing acute wounds
- Wounds where surrounding skin is friable

CONTRAINDICATIONS

- In order not to delay any optimal treatment UrgoStart® is contraindicated in cancerous wounds and fistula wounds which may reveal a deep abscess
- Not suitable for use during hyperbaric treatment
- Do not use if there is a known sensitivity to UrgoStart® or its components

PRECAUTIONS

- If there are clinical signs of local infection, suitable treatment based on clinical judgement and local protocols is recommended prior to the use of UrgoStart®
- In the case of an atypical ulcer presenting induration or over-granulation, UrgoStart® should only be used after checking for the absence of wound-related malignancy in order not to delay the diagnosis

- The product's action on the healing process may possibly cause stinging or painful sensations on commencement of treatment. This rarely warrants suspension of treatment
- Do not re-sterilise the dressing. Single use sterile individual packaging: re-using a single use dressing may lead to risks of infection



Low to moderately exuding wounds (a secondary absorbent dressing can be used for highly exuding wounds)



Can be cut



Can be used under compression

ORDERING DETAILS

CODE	PRODUCT	DESCRIPTION	DRESSING SIZE	DRESSINGS PER BOX
100375	UrgoStart® NA Foam Pad	Protease Inhibiting Matrix Wound Dressing (Foam)	6x6cm	10
100376	UrgoStart® NA Foam Pad	Protease Inhibiting Matrix Wound Dressing (Foam)	10x10cm	10
100377	UrgoStart® NA Foam Pad	Protease Inhibiting Matrix Wound Dressing (Foam)	15x20cm	10
100378	UrgoStart® NA Foam Pad	Protease Inhibiting Matrix Wound Dressing (Foam)	Heel 12x19cm	10

1. Mütter KC, Meaume S, Augustin M, Senet P, Kérihuel J.C. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care. 2017 Feb; 26 (Sup2): S4-S15. Erratum in: J Wound Care. 2017 Mar 2; 26(3): 153.